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Summary 
The p210  ~r/~  tyrosine  kinase  appears to be responsible  for  initiating and maintaining the 
leukemic  phenotype  in  chronic  myelogenous  leukemia  (CML)  patients,  p21~-p120GAP 
interactions play a central role in transducing mitogenic signals. Therefore, we investigated whether 
p21 ~  and p120GAP  are regulated by p210  ~/~  and whether this activation  is functionally 
significant  for CML  cell proliferation.  We report  that  transient  expression  of p210  ~/~  in 
fibroblast-like cells induces simultaneous activation of p21 ~ and inhibition of GTPase-promoting 
activity  of p120GAP, and  confirm  these  data  showing  that  downregulation  of p210  ~/~ 
expression in CML calls with bcr/abl antisense oligodeoxynudeotides induces both inhibition 
of p21 `~  activation  and  stimulation  of GTPase-promoting  activity  of p120GAP.  Tyrosine 
phosphorylation of two p120GAP-associated proteins, p190 and p62, which may affect p120GAP 
activity, also depends on p210  ~/*bl tyrosine kinase expression. Direct dependence of these effects 
on the kinase activity is proven in experiments in which expression of c-MYB protein in fibrobhst- 
like cells or dowrtregnlation of c-MYB expression resulting in analogous inhibition of CML 
cell proliferation does not result in the same changes. Use of specific  antisense oligodeo~'ynudeotides 
to downregnlate p21 ~ expression revealed a requirement for functional p21 ~ in the proliferation 
of  Philadelphia  chromosome-positive CML  primary  cells. Thus,  the  p210~/'bl-dependent 
regulation of p120GAP activity is responsible, in part, for the maintenance of p21 ~ in the active 
GTP-bound form, a crucial requirement for CML cell proliferation. 
T 
he Philadelphia chromosome (Ph  1) is present  in most 
chronic myelogenous leukemias (CML) (1, 2) and in a 
cohort of acute lymphocytic leukemia patients (3). This trans- 
location results in the juxtaposition of the abl gene, normally 
on chromosome 9, and the bcr gene on chromosome 22. The 
bcr/abl hybrid genes generate fusion proteins  in which the 
NH2-terminal region of c-abl is replaced by bcr exon 3, exon 
2 (p210~/as~, or exon 1 (p185~/~  These fusion proteins 
can transform immature hematopoietic cells in vitro (4, 5), 
cause CIVIL or acute leukemia-like syndromes in mice (6-9), 
and are necessary for the growth of human CML cells in vitro 
and in vivo (10, 11). The p210  ~/asl and p185  b'r/*sl proteins 
possess constitutive tyrosine kinase activity, which is neces- 
sary for the transforming potential of the chimeric gene (12) 
and appears to be activated by sequences in the first kr exon 
(13). bcr/abl proteins  are localized mainly in the cytoplasm 
1 Abbreviations used in this paper: CML, chronic myelogenous leukemia; 
CML-BC, CML-bhst crisis; CML-CP, CML-chronic phase; GAP, GTPase 
activating  protein;  Ph  1, Philadelphia chromosome. 
(14). The identification  of the substrates involved in trans- 
ducing the oncogenic signal initiated by the bcr/abl protein 
is likely to shed light on the mechanisms of leukemogenesis 
and may reveal new targets  for antileukemia  therapy. 
The role of p21  ~  in signal transduction and ceU growth 
is weU established, based in part on the observations that func- 
tional wild-type activated p21 ~  (GTP-bound form) is re- 
quired for mitogenic and oncogenic activity of tyrosine kinases 
(15, 16) and for the growth of normal human hematopoietic 
cells (17). p21  ~ activity is regulated by the opposing effects 
of guanine nucleotide exchange factors and GTPase activating 
proteins (GAPs). Exchange factors stimulate the exchange rate 
of GDP for GTP on p21  ~  and thereby activate it (18, 19). 
Activated receptor tyrosine kinases interact with and modu- 
late the activity of the guanine nucleotide exchange factor 
Sos via the GRB-2 protein (20, 21). Recently, the physical 
interaction between p210  ~/~  and GR.8-2,  and its coopera- 
tion with p21 '~ to induce oncogenesis,  have been demon- 
strated in primary routine bone marrow cell cultures and in 
rat fibroblasts (22). 
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tein) stimulate the slow intrinsic rate of GTP hydrolysis on 
p21 r~ and therefore act as negative regulators of p21" func- 
tion (23-26).  p120GAP forms a complex with bcr/abl pro- 
teins through its Src homology (SH)2 domain (27). Tyrosine 
phosphorylation  of p120GAP  and/or  of  the  two  GAP- 
assodated proteins p190 and p62 was described in cells ex- 
pressing bcr/abl (28), and was also observed in cells expressing 
other activated cytoplasmic tyrosine kinases (29, 30) or after 
cytokine stimulation (31). Phosphorylation of p190 and p62 
was found in all CML cases examined,  whereas p120GAP 
phosphorylation occta~ed only in some cases, p120GAP com- 
plexed with p190 has lower GTPase-promoting activity than 
monomeric  p120GAP (30),  which may allow p21 r~ to re- 
main  in  its  active GTP-bound  form.  On  the other  hand, 
p120GAP is also a candidate as a p21 r'~ effector protein and 
may function downstream of p21 '~ in the signal transduc- 
tion pathway (32-34). 
p120GAP may be involved in bcr/abl-dependent  leukemo- 
genesis, based on its physical interaction with the p210  ~/~ 
protein (27) and its requirement in Ph 1 cell growth (35), but 
it is also a well-known negative regulator of p21 ~. Accord- 
ingly, we asked whether p21 r~ is activated by p210  ~/abl and 
is necessary for the proliferation of Ph 1 chromosome-posi- 
tive, kr/abl-dependent CML calls, and whether it regulates 
both p120GAP and p2V  ~ to allow them to work in concert 
in  bcr/abl-dependent  leukemogenesis.  We also investigated 
potential mechanisms of the kr/abl-dependent p21 ~  activa- 
tion, focusing on the two p120GAP-associated proteins, p190 
and p62, which might be involved in the regulation of GTPase- 
promoting activity ofpl20GAP. To this aim, we transiently 
expressed p210  ~/~  in cells to examine the effects of this pro- 
tein on the activation of p21 ~,  the GTPase-promoting  ac- 
tivity of p120GAP, and the tyrosine phosphorylation of p190 
and p62. To complement our findings using cells more rele- 
vant for the functional analysis ofkr/abl, similar experiments 
were  also  carried  out  in  Ph 1 chromosome-positive  CML 
cells in which p210  ~/abl expression was inhibited with bcr/abl 
antisense digodeoxynucleotides. Finally,  the role of p21  ~  in 
the proliferation of CML cells was directly assessed by down- 
regulating  p21 ~  expression  with  antisense  oligodeoxynu- 
cleotides. Our results confirm that the status of p21TM acti- 
vation  in  CML cells  depends  on p210  b'/~  expression and 
produce the first direct demonstration that p210  ~/~bl inhibits 
the GTPase-promoting activity of p120 GAP, thus maintaining 
p21 r~ in an active GTP-bound form in  CML cells. 
Materials  and Methods 
CellLines.  BV173  cells with a t(9;22) chromosomal transloca- 
tion established from a patient  with CML-blast crisis (CMbBC) 
(36), NB4 promyelocytic  leukemia cells with a t(15;17) chromosomal 
translocation  07), HD60 promyelocytic leukemia cells (38), and 
COS-7 simian fibroblast-like cells (39), were maintained in RPMI 
1640 medium supplemented with 10% fetal bovine serum (FBS). 
Syrian hamster Tk-ts13 fibroblasts (40) were maintained in DMEM 
with  10% FBS. 
Primary Cells.  Mononuclear  cells from CMDBC and CMIr 
chronic phase (CP) patients (>50,000//zX white blood cells, >95% 
Ph 1 metaphases) were obtained after separation of peripheral blood 
on Histopaque-1077 (Sigma Chemical Co., St. Louis, MO). Light- 
density mononuclear  cells were incubated on petri dishes for 90 
rain at 37~  to remove most adherent cells. CD34 + cells were iso- 
lated as described using hernatopoietic cellular antigen I mAb and 
polystyrene magnetic beads (17). Recovery of CD34 § cells from 
CML-BC and CML-CP varied between 8 and 41% and 6 and 20%, 
respectively. 
Antisense (AS) and Sense (S) Oligodeoxynucleotides. The following 
phosphorotioate  oligodeoxynucleotides, dissolved in IMDM were 
used:  bcr/abl: 5'-AAGGGCTTCTTCCTTA-Y  (b2/a2  AS)  and 
5'-TAAGGAAGAAGCCCTT-3'  (b2/a2  S);  c-rayb: 5'-TATGCT- 
GTGCCGGGGTCTTCGGGC-Y  (AS) and  5'-GCCCGAAGA- 
CCCCGGCACAGCATA-Y  (S); H-ms:  5'-CAGCTTATATIC- 
CGTCAT-Y (AS) and 5'-ATGACGGAA  TAGCCTG-Y (S); K-ms: 
5'-AAGTTTATATTCAGTCAT-Y (AS) and 5'-ATGACTGAATAT- 
AAACTT-Y (S); and N-ms: 5'-CAGT'Iq'GTACTCAGTCAT-Y (AS) 
and 5'-A_q~ACTGAGTACAAACTG-Y  (S). These compounds were 
synthesized on a DNA synthesizer  (model 380B; Applied Bio- 
systems, Inc.,  Foster City,  CA) by means of •-cyanoethylphos- 
phorimidite  chemistry. They have sequences complementary  (or 
corresponding) to the breakpoint region of the bcr/abl transcripts 
(41), codons 2-9 ofc-myb (42), and codons 1-6 of H-, K-, and N-ras 
mRNAs (43, 44, and 45,  respectively). 
Transfiaion~  Cells  were ~  using the calcium-phosphate 
precipitation method (46) with slight modifications. After trans- 
fection with either  10/zg of pSV-bcr/abl plasmid containing  the 
7.0-kb kr exon 3/abl exon 2 cDNA driven by 5V-40 early promoter, 
pSV-c-myb plasmid containing  a human c-myb full-length cDNA 
driven by the SV-40  early promoter (47), or the empty pSV plasmid, 
the cells were washed and incubated in serum-free medium  sup- 
plemented with 0.1%  BSA (Sigma Chemical Co.). 
Oligoraer Treatment of Cells.  CMUCP or CMUBC cells (10  s) 
were seeded into 24-wen cell culture plates (Costar Corp.,  Cam- 
bridge,  MA) in  0.4  ml  IMDM  supplemented  with  2%  heat- 
inactivated human  AB serum and Hepes buffer. BV173, HD60, 
and NB4 cells (104/100/~l/well)  were placed in 96-weU culture 
plates in RPMI medium supplemented with 10% FBS, L-ghtamine, 
and penicillin/streptomycin.  For protein studies, 5  x  10  ~ BV173 
or HI.-60 cells/20 ml medium were placed in 175-cm  2 LUX tissue 
culture flasks (Nunc, Inc., Naperville~ IL). The tlrst dose of sense 
or antisense oligodeoxynucleotides was added at the beginning of 
culture. The second and third doses (50% of the initial one) were 
added 24 and 48 h later. Control groups were left untreated. Where 
indicated, 50 U/ml IL-3 (Genetics Institute,  Cambridge, MA) was 
added to the primary cell cultures  together with the third  dose 
of oligodeoxynucleotides. Primary cells were incubated for an ad- 
ditional  72 h before plating  in 35-mm petri dishes. The cells in 
96-well plates were counted on days 4, 6, and 8 and viability was 
assessed using the vital dye trypan blue. Cells in flasks were depleted 
of dead cells by density gradient centrifugation on Histopaque-1077, 
and counted before use. 
Colon,/Asa2/s.  Duplicate cultures were prepared in semisolid 
methylcellulose medium (HCC 4230; Terry Fox Labs, Vancouver, 
Canada). I1.-3 and human AB serum concentrations during culture 
were fivefold lower than those used during the oligodeoxynucleo- 
tide treatment.  In some cultures, no ID3 was added. Cultures were 
maintained for 10-12 d, after which plates were scanned with an 
inverted microscope and the number of colonies (;~50 cells) and 
clusters (8-40 cells) were determined. 
Iramunoprecipitation  and Western Blotting.  Cells (2  x  106) were 
solubilized in lysis buffer containing  10 mM Hepes, pH 7.5, 0.15 
M NaC1, 10% glycerol,  10/zg/ml each leupeptin  and aprotinin 
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and 5 mM EDT.A. Postnudear lysates were, if indicated, immuno- 
precipitated (1 h, 4~  with 5 ~,1 of anti-human GAP rabbit serum 
(UBI, Inc., Lake Placid, NY) precoupled to protein A-Sepharose 
(Pharmacia LKB Biotechnology, Piscataway, NJ). The beads were 
washed twice with lysis buffer and twice with 10 mM Hepes, 0.15 
M  NaCI,  and  0.2%  NP-40.  Immunoprecipitated  proteins  were 
eluted in sample buffer, separated on 7.5% SDS-PAGE, and trans- 
ferred to nitrocellulose (Micron Separations Inc., Westboro, MA). 
Filters were saturated with 0.5% gelatin in Tris-buffered  saline (TBS) 
and  then  incubated  (12  h,  4~  with  affinity-purified  an- 
tiphosphotyrosine  rabbit  polyclonal antibody (ICN Biomedicals, 
Inc., Costa Mesa, CA), anti-ABL antibody (48), anti-v-H-ras mAb 
(Oncogene Science Inc., Uniondah, NJ) or anti-c-MYB antibody 
(UBI), as indicated.  Filters were washed five times with 0.25% 
Tween, 0.25% NP-40 in TBS buffer. Bound proteins were detected 
using the enhanced chemiluminescence Western blotting detection 
system (Amersham Corp., Arlington Heights, IL). When indicated, 
after stripping, the filters were blotted sequentially  with anti-human 
heat-shock  protein  (HSP)  72/73  (Oncogene  Science Inc.)  or 
anti-human  p120GAP antiserum,  as controls  for loaded protein 
amounts. 
GTP-bound p21 ~ Assay.  BV173  cells (107) were labeled with 
[32p]orthophosphate  (NEN  Research  Products,  DuPont,  Wil- 
mington, DE) (3 h, 37~  in phosphate-free medium,  and then 
GTP/GDP-bound  p21  ~'  was  determined  as  described  (49). In 
transfected Tk-ts13 and COS-7 cells, GTP-bound  p21  '~ was de- 
tected as described (50). Briefly, cells were washed with serum- 
and phosphate-free RPMI medium and incubated in 4 ml phosphate- 
free RPMI containing  0.25 mCi [32P]orthophosphate. After 3-4 
h at 37~  the cells were washed once with ice-cold PBS, and 0.5 
ml ice-cold buffer (50 raM Tris-HC1, pH 7.5, 20 mM MgC12, 150 
mM NaCI,  0.5%  NP-40,  10/~g/ml aprotinin,  0.5 mM PMSF), 
and finally, 50/~g/ml anti-v-H-ras rat mAb was added. After 1 h 
at  4~  cells were dislodged  by trituration  and  transferred  to 
microcentrifuge  tubes, p21  ~ in the supernatant  was immunopre- 
cipitated using Protein A-agarose coupled to goat anti-rat IgG (On- 
cogene Science Inc.) and  analyzed as described (49). 
Assay of GTPase-lrroraoting  Activity of  p12OGAP.  BV173  (107), 
Tk-ts13 (5  x  106) and COS-7 cells (5  x  106) were assayed for 
GTPase-promoting  activity  using  purified p21N  .... protein  (gen- 
erous gift of  Dr. F. McCormick, Onyx Pharmaceuticals, Richmond, 
CA) bound to c~-[3ZP]GTP, as described (49), in the presence of 
1 mM n-dodecyl-fl-D-mannoside to inhibit  NF-1 activity  (51). 
Results 
p210~/~bt-dependent Model Systems.  Downstream  targets 
of p210  ~r/~  tyrosine kinase  were analyzed in  Tk-ts13  and 
COS-7 cells transiently expressing a full-length bcr/abl  cDNA 
driven by the early SV-40 promoter,  and in the Phi-positive 
cell line BV173 exposed to bcr/abl-specific phosphorothioate 
antisense oligodeoxynucleotides. Tk-ts13 and COS-7 cells were 
chosen for their high transfection efiidency and BV173 cells 
were selected for their exquisite sensitivity to p210  ~/~bl depri- 
vation.  In both Tk-ts13 and COS-7 cells,  p210  ~r/abt expres- 
sion levds, as detected by Western blotting and reaction with 
an anti-ABL mAb, were highest 36-48 h  after transfection 
(Fig.  1 A),  although  the protein was already detectable 12 
h after transfection (data not shown). The appearance of sev- 
eral tyrosine phosphorylated proteins (including one of 210 
kD) in cells  transiently  expressing p210  ~/~bl indicated  that 
the protein had the expected kinase activity. In contrast, trans- 
fection of Tk-tsl3 and COS-7 cells with the pSV vector only 
or with  the pSV vector encoding c-MYB protein  did not 
result in changes in protein tyrosine phosphorylation (Fig. 1 B). 
Incubation of bcr/abl-dependent  BV173 cells with  kr/abl 
antisense oligodeoxynudeotides resulted in a 80-90% decrease 
in expression of p210  ~/abt, but not of HSP 72/73  (Fig.  2), 
the p85 subunit of PI-3 kinase (11), p120GAP, or p21  ~  (data 
not shown). This treatment  also led to complete inhibition 
of cell proliferation (Fig. 2). Proliferation of HL-60 and NB4 
cell lines was not affected by treatment with bcr/abl antisense 
oligodeoxynucleotides (data not shown). BV173 cell prolifer- 
ation was also inhibited after downregulation of c-MYB ex- 
Figure  1.  Expression  of p210  ~/a/ 
and c-MYB proteins and tyrosine 
phosphoryhtion of cellular  proteins 
in  cells transfected with  kr/abl 
cDNA or c-myb  cDNA containing 
plasmids. (A)  Tk-ts13 (/eft) and 
COS-7 ceils  (~ght)  were  transfected 
with pSV-bcr/abl,  or pSV plasmids; 
(B) Tk-ts13 calls were transfected 
with pSV-c-myb  or pSV plasmids. 
After 48 h, total cellular proteins 
were  isolated  from 106  cells, 
divided into two samples, and ana- 
lyzed by Western blotting with 
anti-ABL (rv-ABL), anti-c-MYB 
(o~-c-MYB),  or antiphosphotyrosine 
(o~-P-Tyr) antibodies, as indicated. 
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on BV173 cell proliferation and expression of p210  j'/~  or c-MYB pro- 
teins.  BV173  cells were treated  with  bcr/abl sense  ('-C]-),  c-myb  sense 
(--'0-),  kr/abl  antisense  (-I-),  or c-m'/b antisense  (-O-)  oligodeox- 
ynucleotides  (40+20+20/~g/ml). Control  cells  (-A-) were  left  untreated. 
The number of live cells was counted at the indicated days. Total cellular 
proteins were extracted from 10  ~ cells after 72-h incubation  with sense 
(S) or antisense (AS) oligodeoxynucleotides. Control (C) cells were left 
untreated. BCR/ABL and c-MYB proteins were detected in lysates of cells 
treated with bcr/abl  or c-rr~b  oligodeoxynudeotides, respectively, by Western 
blotting using specific  antibodies to c-ABL or c-MYB.  HSP 72/73 was 
detected on the same filters with anti-HSP 72/73 antibody.  (~p) kr/abl 
oligodeoxynudeotide-treated cells;  (bottom) c-myb oligodeoxynucleotide- 
treated  cells. 
pression by antisense oligodeoxynucleotide treatment (Fig. 
2). Thus, effects due to specific inhibition of p210 ~'/~  tyro- 
sine kinase expression can be distinguished from those that 
may be consequent to inhibition  of ceil growth per se. 
p2I ~  Activation  in  Cells after  Induction  or  Inhibition  of 
p210  ~/"bl Expression.  Transient expression  of p210  ~/"bt tyro- 
sine kinase resulted in  a  three- to fourfold increase in  the 
amount of GTP-bound p2F  ~  as measured in Tk-ts13  and 
COS-7 ceils 48 h after transfection with pSV-kr/abl plasmid, 
relative to the levels in cells transfected with the pSV empty 
plasmid (Table  1). The three- to fourfold increase in GTP- 
bound p21 '~  likely underestimates the effects of p210 ~/~bl, 
because at most 70% of the cells are expected to be p210  ~/"bl 
positive after transfection (40). Transient expression of c-MYB 
protein, which is essential for the growth of bcr/abl-dependent 
cells,  but  most  likely acts  downstream of p21'%  did  not 
affect the ratio of GTP/GDP associated with p21 ~  (Table 1). 
To further examine the role of p210 ~r/'u in the activation 
of p21 ~  in leukemic cells carrying the Phi-chromosome, the 
active GTP-bound p21 ~  was measured in BV173  cells ex- 
posed to bcr/abl-specific antisense oligodeoxynucleotides for 
72 h to inhibit p210 ~/"u expression. After the culture, dead 
ceils were depleted by density gradient centrifugation and 
biochemical analysis was conducted on an equal number of 
ceils from treated and control cultures. Downregulation of 
p210 ~/'bl expression was associated with a sevenfold decrease 
in GTP-bound p21 ~  as compared with untreated, or sense- 
treated cells (Table 2).  In control experiments, downregula- 
tion of c-MYB expression was concurrent with inhibition 
of BV173 proliferation, but did not change the amount of 
GTP-bound p21 ~  (Table 2), thus demonstrating the speci- 
ficity in the linkage between p210 ~/"bl expression and p21 '~ 
activation. 
Effect of Inhibition of  p21 '~' Expression on Growth of bcr/abl- 
dependent Cells.  To obtain direct demonstration that p21 ~ 
plays a role in the growth of Ph  1 chromosome-positive cells, 
whose proliferation depends on p210 ~/'u expression, BV173 
cells were treated with antisense oligodeoxynucleotides tar- 
geted against codons 1-6 of H-, K-, and N-ras exon 1. BV173 
and primary CML cells expressed the mRNA of each of the 
three ras genes as detected by RT-PCR  (data not shown). 
p21 ~  protein levels were decreased by treatment with the 
mixture of H-,  K-,  and N-ras antisense, but not with the 
mixture of sense oligodeoxynucleotides (Fig. 3 B). Prolifera- 
tion of BV173 cells was concurrently completely inhibited 
by the antisense but not by the sense oligodeoxynucleotide 
mixture (Fig.  3 A). Of several different oligodeoxynucleo- 
tide concentrations tested, 8+4+4/~g/ml was the lowest that 
gave maximum inhibition of BV173 cells. In paralld experi- 
ments, the growth of two cell lines nondependent on bcr/abl 
or growth factors (HL-60 and NB4) was not affected (Fig. 
3 A), even though p21 r~ expression was inhibited by the an- 
tisense oligodeoxynucleotide mixture in HL-60 cells (Fig. 3 
C) and treatment within a fourfold higher concentration of 
Table  1.  Activation  of p21 '~ in  Tk-ts13  and  COS-7  Cells 
upon Expression of p210  ~'/"b~ or c-MYB Proteins 
Cells  pSV  pSV-bcr/abl  pSV-c-myb 
COS-7  5.1  +  0.8  23.7  _+ 4.7*  ND 
TK-ts13  7.1  +  2.7  23.3  +  1.0'  7.4  _+ 0.6 
The indicated cells were transfected with the pSV plasmid, empty or con- 
taining bcr-abl or c-rayb, as indicated,  p21~  activation was analyzed af- 
ter 48 h. 
The results are expressed as percent GTP-bound/GTP plus GDP-bound 
p21~,  mean  +  SD,  three experiments. 
p  =  0.03. 
*p  =  0.001,  pSV-bcr/abl  group  compared with pSV group  (Student's 
t  unpaired  test). 
Table  2.  Influence  of p210 ~/"bt or c-MYB  Protein 
Downregulation  on p21 ~  Activation  in  BV173  Cells 
Oligodeoxynucleotide  treatment 
Oligomers  None  Sense  Antisense 
bcr/abl  7.0  +  0.8  7.4  +  1.8  1.1  _+  1.5" 
c-myb  7.9  +  0.9  7.8  _+  1.5  7.6  +  1.3 
BV173 cells were exposed to the indicated oligodeoxynucleotides for 72 h, 
after which p21  "~ activation was determined.  The results  are expressed 
as percent GTP-bound/GTP  plus GDP-bound p21  ~, mean  _+  SD, three 
(kr/abl)  and  two  (c-raft)  experiments,  respectively. 
p  =  0.01, bcr/abl anfisense versus bcr/abl sense and c-raft antisense group. 
(Student's  t  unpaired  test). 
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dependent and -independent cell lines. (A) The indicated ceils were treated 
with a mixture of H-, K-, and N-ras sense (-O-) or antisense  (-II--) 
oligodeoxynudeotides (40+ 20+ 20/~g/ml). Control (--/~) cells were left 
untreated. The number of live cells was scored at the indicated days (ex- 
periment representative of four performed). Total proteins (B and C) were 
isohted from 106 ceils after 72-h incubation,  p21  '~ protein and HSP 72/73 
in BV173 (B) or HL-60 cells (C) were detected on the same falter  by Western 
blotting using specific antibodies. Results are representative of two inde- 
pendent experiments. 
oligodeoxynudeotides did not show any effect in these lines 
(data not shown). 
To determine whether p21'*' is also directly involved in 
the  growth  of  Ph  1 chromosome-positive  primary  ceils, 
CML-CP and CML-BC primary cells were incubated with 
the mixture of H-, K-, and N-ras antisense or sense oligo- 
deoxynucleotides  and their colony-forming ability was ana- 
lyzed in a clonogenic assay with or without IL-3.  Control 
cells were left untreated. Clonogenic growth of CML-CP 
and CML-BC ceils was significantly inhibited by treatment 
with the antisense, but not sense oligodeoxynucleotide  mix- 
ture (Table 3). All together, the results of these experiments 
indicate that proliferation of CML ceils depends on p21  '~ ex- 
pression. 
GTPase-promoting Activity of  p12OGAP in Cells after Indue- 
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tion or Inhibition of  p210  ~'/abl  Expression.  GTPase-promoting 
activity of p120GAP was assessed  in cell lysates from Tk-ts13 
or COS-7 ceils  48 h after transfection with pSV-kr/abl phsmid 
or pSV empty plasmid.  Assays were done, in the presence 
of 1 mM n-dodecyl-/3-D-marmoside  to inhibit NF-1 activity, 
using purified p21  tr  coupled to c~-[3ZP]GTP as a substrate. 
p210  b'/~  expression and protein tyrosine phosphorylation 
were examined in each experiment.  The amounts of ot-[32P] 
GTP that remained bound to p21N-r~ after a 10-min incu- 
bation  with  20  and  75  /xl  of ceil lysate  from p210  b'/~ 
expressing Tk-ts13 cells (60.1% and 45.1, respectively) were 
higher than those measured after incubation with lysates  from 
cells not expressing p210  ~/'u (46.6 and 19.2%, respectively) 
(Fig.  4  A).  Cell  lysates  from  COS-7  cells expressing 
p210  ~'/~  also showed reduction in GTPase-promoting ac- 
tivity of p210GAP  (in  20  and  75  /zl  of ceil  lysate from 
p210~'/~  ceils, 67.2 and 64.8% of p21  ~  was in 
the GTP-bound form versus 62.4 and 51% of nonexpressing 
ceils, respectively) (Fig. 4 B). These experiments suggest that 
transient  expression  of p210  s'r/'bz tyrosine kinase  in trans- 
fected  cells  reduces  the GTPase-promoting activity of pI20GAP. 
After treatment with 20 and 75 #1 of BV173 ceil lysates ob- 
tained after 72-h incubation of the ceils with kr/abl phos- 
phorothioate antisense oligodeoxynudeotides, only 44.0 and 
6.9% of p21N'*' remained in the c~-[3zp]GTP-bound form. 
In contrast,  58 and 31.1%  of p21  tr  was in ot-[32p]GTP  - 
bound form after incubation with 20 and 75/~1, respectively, 
of ceil lysates  obtained from sense oligodeoxynudeotide-treated 
ceils (Fig. 4 C). Compared with sense oligodeoxynucleotide- 
treatM  ceils, ceil lysates from untreated ceils had similar 
p120GAP activity. Downreguhtion of c-MYB expression was 
also associated with inhibition of BV173 ceil growth, but 
this did not affect the GTPase-promoting activity of p120GAP, 
as compared with the control group (Fig. 4 C'). This argues 
against the possibility that the observed changes in p120GAP 
activity were due to  inhibition of ceil proliferation,  and 
confirms  that  downregulation  of  p210  ~r/asJ  expression 
specifically  results in enhancement of the GTPase-promoting 
activity of p120GAP. 
Phosphorylation  of  ~I2OGAP and of tu,o GAP-associated  Pro- 
reins, p190 and p62 aJter Induction or Inhibition  of  p1210  ~/*u Ex- 
pression.  Tyrosine phosphorylation ofpl20GAP and of two 
p120GAP-associated proteins,  p190 and p62, was examined 
using antiphosphorotyrosine antibody (c~-P-Tyr)  in Western 
blots of p120GAP immunoprecipitates from the ceils tran- 
siently expressing p210  ~'/~  p120GAP was not phosphory- 
lated in ceils expressing p210  ~/~  tyrosine kinase, but tyro- 
sine phosphorylation of p190 was three- to fourfold higher 
as compared with that  in ceils transfected  with insertless 
plasmid (Fig. 5 A). No tyrosine phosphorylation of p62 was 
detected in cells transfected with the insertless plasmid even 
after  long exposure  of the blot,  whereas the band corre- 
sponding to p62 was intense in ceils transfected with the pSV- 
bcr/abl  plasmid (Fig. 5 A). Equal amounts of immunoprecip- 
itated pl20GAP were detected on the same blot. 
To  analyze whether p210  ~'/~bl tyrosine kinase  regulates 
tyrosine phosphoryhtion of p120GAP, p190, and p62 in CML 
ceils, phosphorylation of these proteins was examined in BV173 Table  3.  Effect of Inhibition of p21 ~  (H-ras, K-ras, and N-ras) Expression on In  Vitro Colony Formation by CML Primary Cells 
Oligodeoxynudeotide  treatment 
Cells  IL-3  Control  Sense  Antisense  Percent  inhibition 
CML-CP  1"  -  310  +  16*  317  +  38  125  _+  35  61  (p  =  0.001)s 
CML-CP 2  +  400  +  26  458  +  14  148  _+  23  68  ~  =  0.004) 
CML-CP 3  +  120  +  13  104  ,+  4  29  _+  9  72  (p <0.001) 
+11  27  _+  7  22  ,+  4  4  ,+  1  82  (/,  =  0.001) 
CML-CP 4  +  378  _+  21  378  ,+  67  106  ,+  4  72  ~  =  0.03) 
CML-BC  1  -  225  _+  19  215  ,+  24  92  _+  37  57  (p  =  0.001) 
+  1,120  +  196  1,042  ,+  189  454  ,+  149  56  (p <0.001) 
CML-BC 2  +  120  _+  17  119  ,+  13  15  +  7  87  (/, <0.001) 
CML-BC 3  +  507  +_ 97  468  ,+  101  113  _+  11  76  (p <0.001) 
+ll  67  ,+  13  67  ,+  13  31  _+  4  54  (p <0.001) 
CML-BC 4  +  1,355  _+  426  1,280  ,+  187  305  _+  13  76  (p <0.001) 
+11  655  _+  35  630  +  60  259  _+  16  59  (p  =  0.01) 
CML-BC 5  +  597  _+  13  604  ,+  54  155  _+  35  76  (p <0.001) 
+ II  240  _+  38  216  ,+  18  58  _+  15  73  (p <0.001) 
CML-BC 6  -  69  _+  9  59  ,+  10  6  _+  1  90  (p  =  0.017) 
+  329  +  72  331  +  37  147  _+  27  56  (/, <0.001) 
+11  148  _+  29  138  ,+  42  24  _+  11  83  (p  =  0.002) 
CML-BC 7  +  359  _+  30  360  ,+  45  105  _+  16  71  (p  =  0.017) 
CML-BC 8  +  142  _  8  107  .+  9  33  ,+  3  69  (it,  =  0.008) 
160 or 80/tg/ml of the R/IS oligodeoxynucleotides  mixture was  added  at  time 0 and  the next two doses (each one half of the first  dose) were 
added 24 and 48 h later.  Cells (5  x  104 partially  purified  mononuclear  cells or 5  x  103 CD34 + cells per plate)  were phted after  120 h culture. 
Bcr/abl antisense oligodeoxynucleotide  treatment inhibited colony formation by 40-50% (CML-CP) and 60-90% (CML-BC) in comparison  with 
sense treatment. 
* PBMC were obtained  from 12 CML patients,  as indicated. 
t Numbers are colonies per phte,  mean of triplicates  •  SD. 
S Inhibition of colony formation by antisense versus sense oligodeoxynudeotide treatment.  Statistical  significance (by Student's  t unpaired  test)  is 
reported in parentheses. 
II CD34 + cells were used. 
cells in which p210  b'r/~bl expression was inhibited by incuba- 
tion with bcr/abl-spedfic antisen~/e  oligodeoxynucleotides. The 
amount of tyrosine phosphorytated p190 and p62 immuno- 
precipitated with p120GAP in cells treated with bcr/abl-specific 
antisense oligomers was lower than that in ceils treated with 
the sense oligomers (Fig. 5 B), although the amount of im- 
munoprecipitated GAP was similar in each lane. Again, no 
tyrosine phosphorylation of p120GAP (Fig. 5 B) was detected 
in BV173 cells expressing p210  ~/~  tyrosine kinase (sense- 
treated cells). Similar results were obtained in two indepen- 
dent experiments with BV173 cells using antisense oligodeoxy- 
nucleotides at 80+40+40 or 40+20+20/~g/ml,  and with 
primary CML-BC cells using oligodeoxynucleotide  concen- 
trations of 160 + 80 + 80/~g/ml (data not shown). To exclude 
the possibility that kr/abl antisense oligumers inhibit phos- 
phorylation of p190 and p62 nonspecifically, K562 cells (Ph 1 
chromosome-positive with  b3/a2  breakpoint  (41)) were 
treated  with b2/a2 antisense oligudeoxynudeotides which 
do not interact with the b3/a2 transcripts  and do not affect 
p210  b'r/~l levels in K562 cells (Skorski, T., unpublished ob- 
servation). Indeed, phosphorylation of p62 and p190 on tyro- 
sine residues was not affected (data not shown). Moreover, 
inhibition of BV173 cell growth upon downregulated c-MYB 
expression by treatment with c-rayb antisense oligodeoxy- 
nucleotides did not change the phosphorylation of p190 and 
p62 (Fig. 5 B). Thus, p210 ~/~bt tyrosine kinase does not in- 
duce phosphoryhtion ofpl20GAP but reguhtes tyrosine phos- 
phorylation of the p190 and p62 proteins, which are physi- 
cally associated with p120GAP. 
Discussion 
This  study  was  undertaken  to  determine  whether  p21 'a~ 
and p120GAP,  two  signal  transduction  pathway  molecules 
possibly involved in kr/abl-induced leukemogenesis, are regu- 
lated  by  p210 ~r/~bl tyrosine  kinase.  We  used  two  separate 
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Figure 4.  Effect of p210  ~/~ expression on GTPase-promoting activity 
of p120GAP. Tk-tsD (,4) and COS-7 cells (B) were transfected with pSV- 
kr/abl (11) or pSV plasmids (O). BV173 cells (C) were treated with bcr/abl 
sense (A) bcr/abl antisense (11) or c-rnTb antisense (A) oligodeoxynucleo- 
tides (40+20+20/~g/ml), or left untreated (O). After 48 (A and B) or 
72 h (C), cell lysates were prepared and assayed for GTPase-promoting 
activity on  p21 '~ using recombinant  p21N~  coupled to  o~-[3zp]GTP. 
Results are expressed as percent GTP-bound/GTP plus GDP-bound forms 
of p21N'~ from two independent e~periments.  Bars are SD. 
experimental  approaches:  transient  expression of p210  ~'/abt 
protein in fibroblasts and downregulation of p210  ~'/~bt ex- 
pression in Philadelphia chromosome-positive cells by their 
exposure to antisense oligndeoxynudeotides directed against 
bcr/abl mRNA. Results obtained with both approaches  indicated 
that the status of p21 '~ activation depended on p210  ~/~bt ex- 
pression.  Transient  expression  of p210  ~/~  upon  cDNA 
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transfection  in Tk-tsD and COS-7 cells stimulated p21% 
as indicated by the increased amount of its GTP-bound form. 
Conversely,  selective inhibition of p210  ~'/~  expression in 
CML cells by bcr/abl-targeted  antisense oligodeoxynucleotides 
resulted in diminished GTP-bound p21  '~. In control experi- 
ments, the human c-MYB protein, a transcriptional  regu- 
lator that presumably functions only in the nucleus, did not 
affect p21 r~.  The antisense  oligodeoxynudeotide strategy 
was previously employed by others (52, 53) to inhibit p21  '~ 
expression. Our results using this approach directly demon- 
strate that p21 '~ is necessary for the proliferation  of CML 
cells and suggest that its activation by p210  ~'/abl plays a cru- 
cial role in bcr/abl-induced leukemogenesis. 
The  possibility  that  an  oncogenic point  mutation  in 
p21%  rather than the stimulation of wild-type p21  ~  by 
p210  ~'/~  is responsible for its constitutive activation  and 
consequent proliferation of CML calls, especially CML-BC, 
is unlikely because oncogenic point mutations in the RAS 
genes are rarely found in CML (54-56).  N-ras point muta- 
tions have been detected in a very small group of CML-BC 
patients (56). We have detected no point mutations in N-ras 
exon 1 and exon 2 in several CML-BC patients whose N-ras 
we sequenced (Skorski, T., unpublished data). Thus, together 
with  our  previous  findings  that  proliferation  of growth 
factor-stimulated normal bone marrow progenitor ceils de- 
pends on wild-type p21  ~  (17), the results reported here sup- 
port a primary role for wild-type p21  '~ as a key signal trans- 
ducing molecule in Ph  I chromosome-positive  hematopoietic 
cells. Presumably, in the leukemic calls, p21  ~ is abnormally 
activated by p210  ~/'~l, resulting in disruption of the mech- 
anisms regulating ligand-receptor-activated  signal transduc- 
tion pathways. 
Tyrosine kinases might activate p21  '~ proteins  through 
distinct pathways, depending on the call type and on condi- 
tions that favor a particular pathway among several alterna- 
tives, p21  ~ activation correlates with decreased p120GAP ac- 
tivity in T and B cells after activation by PHA and antigen, 
respectively (49,  57). Binding of epidermal  growth factor 
(EGF) to its receptor stimulates p21 ~' (58) by changing the 
intracdhlar localization of guanine nudeotide exchange factor, 
thus modulating its access to the substrate,  and decreasing 
p120GAP GTPase-promoting activity (59).  Nerve growth 
factor stimulates both exchange factor and GTPase-promoting 
activities (60), and p21 r~ activation is controlled by the bal- 
ance in activity between these two regulatory proteins. The 
mechanism(s) of p21 r~ activation by p210  ~/'bl in CML cells 
is poorly understood. However, a recent publication (22) sug- 
gests that the GRB-2/Sos pathway may be involved. The as- 
sodation of BCR/ABL protein with GRB-2 reported in that 
manuscript is required for the activation  of the p21 '~ sig- 
naling pathway in transfected fibroblasts and for transforma- 
tion of fibroblasts and murine bone marrow cultures. 
Because p210  ~/~  is complexed with p120GAP in CML 
ceUs (28, 35)  and activated p21  '~  (this  report),  we inves- 
tigated whether the latter effect depends on modulation of 
GTPase-promoting  activity of p120GAP. Using two distinct 
approaches to modulate p210  ~/~  expression i.e., transient 
expression in fibroblasts and inhibition by antisense oligode- Figure  5.  Effect  of expression of 
p210  ~/ou and c-MYB on the phos- 
phorylation  of  p190  and  p62 
p120GAP-associated protdns.  (A) 
Tk-ts13 and COS-7 cells were trans- 
fected  with  pSV-kr/abl  or  pSV 
empty plasmids;  (B)  BV173 cells 
were  treated with 40,  20, and 20 
pg/ral of kr/ab| or c-myb  antisense 
(AS) or sense (S) oHgodemrynudeo- 
tides,  as indicated,  p120GAP im- 
munoprecipitates  were  obtained 
from cell lysates after 48-h (A) or 
72-h (B) incubation and analyzed  se- 
quentially by Western blotting with 
antiphosphotyrosine  (top)  and anti- 
p120GAP antibodies  (bottom). 
oxynucleotides in CML cells, we demonstrate that p210  ~/ab! 
negatively  regulates  the  GTPase-promoting  activity  of 
p120GAP. Again, deregulation of c-MYB expression in CML 
calls did not affect p120GAP activity. These results strongly 
support  the conclusion that activation of p21 ~ by p210  ~/*bt 
tyrosine kinase in CML cells depends,  at least in part,  on 
inhibition of GTPase-promoting  activity of p120GAP. It is 
possible that both p120GAP-dependent (this paper) and GRB- 
2/Sos-dependent  (22) mechanisms of p21  r~ activation work 
in concert in kr/abl-dependent leukemic cells, p210  ~/~  may 
activate p21  ~ via GRB-2/Sos  and, at the same time, inhibit 
the rate of p21 '~ inactivation  (hydrolysis of GTP-p21 `~ to 
GDP-p21~),  decreasing the GTPase-promoting  activity of 
p120GAP. The existence of the GRB-2/Sos activation mech- 
anism awaits, however, confirmation in Ph t chromosome- 
positive cells. 
The mechanism(s) by which p210  ~/~bl might regulate the 
GTPase-promoting  activity of p120GAP was analyzed. Two 
proteins, p190 and p62, are tyrosine phosphorylated and are 
associated with p120GAP in cells expressing oncogenic tyro- 
sine kinases,  including p210  ~/~  (61, 30,  62). p190 was 
shown to inhibit in vitro GTPase-promoting  activity when 
complexed with p120GAP (30). Our experiments expand this 
observation  to  show that  p210  b'r/~  but  not  c-MYB,  in- 
creases the proportion of tyrosine phosphorylated p190 and 
p62 detected in complex with p210GAP, which is not tyro- 
sine phosphoryhted. Elevated  levds of tyrosine phosphoryhted 
p190 complexed  with  p120GAP correlate  with  increased 
amount of GTP-bound p21 r~ (62, 63). This raises the pos- 
sibility  that  p210  ~/*bl inhibits  the  GTPase-promoting  ac- 
tivity of p120GAP by increasing the tyrosine phosphoryla- 
tion  of p190 complexed  with  it.  Alternatively,  p210  b'r/~ 
might bind p120GAP and inactivate it or make it less avail- 
able for interaction with p21  ~. The first mechanism was de- 
scribed for activated EGF receptor  (59). 
The consequence(s)  of p21r~-p120GAP interaction is  a 
matter of controversy (32, 64). The COOH-terminal region 
of p120GAP is suffident to accelerate p21  ~ GTPase activity 
and therefore to inactivate p21TM (65). The NHz-terminal re- 
gion contains two SH2 domains and an intervening SH3 do- 
main, all implicated in the interactions between tyrosine ki- 
nases and their target molecules (66). p120GAP interacts with 
the domain of p21  `~ that has effector function (67), and it 
has been suggested that GAP serves both as a target for acti- 
vated p21 '~ (33, 34) and as its negative regulator (25, 26). 
Hence, the transient  interaction  of p120GAP  with p21 '~- 
GTP at the plasma membrane might simultaneously induce 
GTP hydrolysis and generate a downstream signal involving 
a p120GAP-associated activity or protein. Indeed, p120GAP 
SH2-SH3 domains,  or the SH3 domain per se, may trans- 
duce signals from p21  r'~ to activate los promoter in mam- 
malian cells (33) and to block germinal vesicle breakdown 
induced by oncogenic H-ras in Xenopus oocytes (34). p21  r~- 
GTP interacts with the COOH-terminal region of p120GAP 
and is consequently altered to p21"~-GDP. This reaction is 
thought to induce a conformational change(s) in the SH2- 
SH3 domains, allowing them to interact with phosphorylated 
proteins  (33). 
These observations may explain the role of p120GAP in 
p210~/*bl-dependent cells both as signal transducer (35), and 
as negative regulator of RAS activity (this paper). Here, we 
report that the amount of tyrosine phosphorylated p190 and 
p62 complexed to p120GAP is increased by p210  ~/a~l. This 
may allow the formation of p120GAP-p190 and/or p120GAP- 
p62 complexes which may either regulate the transduction 
of mitogenic signals through p21 r~ or transduce  a signal 
from p21 '~ or directly from p210  s'r/abl, p190 and p62  are 
localized both in the cytoplasm and in the nucleus (62, 68). 
p62  has  extensive  sequence  homology with  the putative 
hnRNP protein GRP33, binds to DNA and RNA (68), its 
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forming activity of p210  ~/~  (69), and it has been proposed 
to provide a link between phospholipase  C  (PLC3,-1)  and 
p21 ~  activation pathways (70).  p190,  in addition  to regu- 
lating the GTPase-promoting activity of p120GAP, may func- 
tion as a transcriptional repressor (61) and may serve as a bridge 
between ras and rho signal transduction pathways (71). Thus, 
it is possible that p62 and p190 have signal transducing func- 
tions on their own. 
In summary, we directly proved the hypothesis that p21 ~ 
expression is necessary for the kr/abl-dependent proliferation 
of Ph 1 CML cells. Our data demonstrate that p210  ~/*u tyro- 
sine kinase  stimulates  p21 r~ activity and inhibits  GTPase- 
promoting activity of p120GAP, which may help p21  '~ to 
remain  in  an  active GTP-bound  form in  CML cells.  The 
amount of tyrosine phosphorylated p190 and p62 proteins de- 
tectable in complex with p120GAP is increased by p210  ~/abt, 
suggesting that these proteins may regnlate GTPase-promoting 
activity of p120GAP and/or serve as signal transducing mol- 
ecules in  bacr/abl-dependent  leukemogenesis. 
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